Mindset Pharma Inc. (OTCQB: MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds.

Since its formation, Mindset has the goal of taking drug discovery from known psychedelics within the tryptamine drug class (such as psilocybin and DMT) to expand a portfolio of drug candidates for neuropsychiatric conditions. 

This time, Mindset’s scientists combined a fragment-based drug discovery (FBDD) method with a highly focused …

Full story available on Benzinga.com